Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections

Article activity feed

1. Version published to 10.1128/jcm.01717-21

   Jan 19, 2022
2. 

   ScreenIT

   Aug 19, 2021

   SciScore for 10.1101/2021.08.10.21261841: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: Ethics: This work was approved by the Research Ethics Boards of the Research Institute of the McGill University Health Centre (RI-MUHC # 2021-7246).
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   SARS-CoV-2 antibody testing: Three different SARS-CoV-2 antibody-detection assays were selected to assess the specificity of assays that detect different analytes, including anti-SARS-CoV-2 N-protein IgM, anti-SARS-CoV-2 N-protein IgG, and anti-Receptor Binding Domain (RBD) blocking antibodies of all immunoglobulin subclasses.	anti-Receptor Binding Domain (RBD suggested: None
   Statistic…

   SciScore for 10.1101/2021.08.10.21261841: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: Ethics: This work was approved by the Research Ethics Boards of the Research Institute of the McGill University Health Centre (RI-MUHC # 2021-7246).
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   SARS-CoV-2 antibody testing: Three different SARS-CoV-2 antibody-detection assays were selected to assess the specificity of assays that detect different analytes, including anti-SARS-CoV-2 N-protein IgM, anti-SARS-CoV-2 N-protein IgG, and anti-Receptor Binding Domain (RBD) blocking antibodies of all immunoglobulin subclasses.	anti-Receptor Binding Domain (RBD suggested: None
   Statistical analysis: Because all specimens were collected in the pre-pandemic era, prior to July 2019, all positive results for SARS-CoV-2 antibodies were considered false positives.	SARS-CoV-2 suggested: None
   Software and Algorithms
   Sentences	Resources
   Abbott SARS-CoV-2 IgG assay: The Abbott SARS-CoV-2 IgG assay (Abbott Laboratories, Abbott Park, Illinois, USA), which detects IgG against SARS-CoV-2 N-protein, was performed on the Architect i2000sr platform according to the manufacturer’s instructions.	Abbott Laboratories suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Limitations of our study include the fact that the available volume of stored pre-pandemic specimens precluded the possibility of performing specific avidity testing or assessing for the presence of antibodies to seasonal coronaviruses that may have cross-reacted with the SARS-CoV-2 serological assays. However, a report from the United States found no false positives for Abbott Architect or SD RDT IgM/IgG among 21 patients with recent seasonal coronavirus infections: NL63 (n = 11), HKU1 (n = 7) and 229E (n = 3) (23). Moreover, the fact that our data recapitulates findings from previous studies in malarial-endemic areas is reassuring regarding their robustness.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.08.10.21261841v1 on medRxiv

   Aug 12, 2021